We were excited to hear that Liquidia has filed with the FDA for approval of their drug inhaled treprostinil. They had already reported exciting results with their medication, showing that it was well tolerated and maintained or improved six minute walk distance.   Currently, United Therapeutics makes Tyvaso, which is treprostinil for inhalation.  Tyvaso … [Read more...]

PULSAR Phase 2 Study Results This was a very exciting week in the world of pulmonary arterial hypertension.  Acceleron announced the results of their PULSAR phase 2 study.  This study used Sotatercept, a novel drug, to treat PAH.  It was given as a subcutaneous (under the skin) injection every three weeks.  The primary endpoint of … [Read more...]

Serotonin is an important molecule in our bodies.  It works in our brain to regulate mood, appetite, sleep, memory and probably many other aspects of our behavior.  In the 1960’s and early 1970’s a drug called Aminorex was sold in Europe as a prescription weight loss medication.  It was withdrawn from the market in the early 1970’s after doctors … [Read more...]

Historic Treatment of Pulmonary Hypertension  For 30 years the focus of treating PAH has been finding medications that dilate (or relax) the pulmonary arteries.  This approach has served patients well.  The prognosis for patients diagnosed today with PAH is very different from 30 years ago.  Today patients can expect to take usually two if … [Read more...]